Skip to main content
. 2017 Nov 28;180(2):224–235. doi: 10.1111/bjh.15025

Figure 1.

Figure 1

Kaplan–Meier curves of PFS in the lenalidomide versus IC treatment arms for all patients (A) and for patient subgroups with age ≥65 years (B), advanced MCL stage III/IV at diagnosis (C), high LDH at baseline (D), high tumour burden at baseline (E), bulky disease at baseline (F) and disease refractory to last treatment (G). 95% CI, 95% confidence interval; HR, hazard ratio; IC, investigator's choice; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; PFS, progression‐free survival.